Compare Natera Inc. Common Stock (NTRA) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs US Bancorp — how do they compare? Natera Inc. Common Stock trades at $392.22 (market cap $57.03B), while US Bancorp trades at $56.26 (market cap $88.64B). The key difference: US Bancorp is the larger of the two by market cap, and US Bancorp pays a 3.8% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and US Bancorp for 98 Days on average.
| NTRA | USB | |
|---|---|---|
Market Cap | $57.03B | $88.64B |
Volume | 1,131,157 | 8,200,583 |
Sector | Health | Financials |
52-Week High | $425.64 | $65.42 |
52-Week Low | $179.42 | $45.47 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $56.18B | $118.14B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
U.S. Bancorp (USB) trades at $56.26, down 2.02% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with a P/E of 11.36 and net income margin of 27.61%, having beaten earnings estimates for three consecutive quarters. Recent news highlights dividend increases and strong Q3 expectations, while analyst consensus remains positive with a $69.94 price target.
USB presents a value opportunity with attractive valuation metrics and consistent earnings outperformance, though near-term technical weakness and regulatory uncertainties pose risks. The stock's 3.8% dividend increase signals management confidence, but investors should monitor interest rate sensitivity and competitive pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
